Matrix metalloproteinase inhibitor, MMI270 (CGS27023A) inhibited hematogenic metastasis of B16 melanoma cells in both experimental and spontaneous metastasis models

Clinical and Experimental Metastasis

Volumn 25, Issue 7, 2008, Pages 827-834

  Kasaoka, Tatsuhiko ^a   Nishiyama, Hiroko ^a   Okada, Mikiko ^a   Nakajima, Motowo ^a,b  

^a NOVARTIS PHARMA K K   (Japan)

^b New Business and Technology Transfer   (Japan)

Author keywords

Lymphadenectomy; Melanoma; Metastasis; MMI270 (CGS27023A); MMP

Indexed keywords

CGS 27023A; MATRIX METALLOPROTEINASE INHIBITOR; MELANIN; MM 1270; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DERMIS; DRUG BLOOD LEVEL; DRUG MECHANISM; FOOT PAD; LUNG METASTASIS; LYMPH NODE METASTASIS; LYMPHADENECTOMY; MALE; MELANOMA CELL; METASTASIS INHIBITION; MOUSE; NONHUMAN; OSMOTIC PUMP; STRUCTURE ACTIVITY RELATION; TARGET ORGAN; TISSUE SECTION;

ANIMALS; HYDROXAMIC ACIDS; LUNG NEOPLASMS; MALE; MATRIX METALLOPROTEINASES; MELANOMA, EXPERIMENTAL; MICE; NEOPLASM METASTASIS; PROTEASE INHIBITORS; PYRAZINES; SULFONAMIDES;

EID: 53949121835     PISSN: 02620898     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10585-008-9198-7     Document Type: Article

References (28)

1. LJ McCawley LM Matrisian 2000 Matrix metalloproteinases: multifunctional contributors to tumor progression Mol Med Today 6 149 156 10.1016/S1357-4310(00) 01686-5
2. H Nagase JF Woessner 1999 Matrix metalloproteinases J Biol Chem 274 21491 21494 10.1074/jbc.274.31.21491
3. WG Stetler-Stevenson 1999 Matrix metalloproteinases in angiogenesis a moving target for therapeutic intervention J Clin Invest 103 1237 1241 10.1172/JCI6870
4. DE Gomez DF Alonso H Yoshiji 1997 Tissue inhibitors of metalloproteinases: structure, regulation and biological functions Eur J Cell Biol 74 111 122
5. SM Wojtowicz-Praga RB Dickson MJ Hawkins 1997 Matrix metalloproteinase inhibitors Invest New Drugs 15 61 75 10.1023/A:1005722729132
6. S Curran GI Murray 1999 Matrix metalloproteinases in tumour invasion and metastasis J Pathol 189 300 308 10.1002/(SICI)1096-9896(199911)189:3<300:: AID-PATH456>3.0.CO;2-C
7. R Fridman M Toth D Pena 1995 Activation of progelatinase B (MMP-9) by gelatinase A (MMP-2) Cancer Res 55 2548 2555
8. WG Stetler-Stevenson S Aznavoorian LA Liotta 1993 Tumor cell interactions with extracellular matrix during invasion and metastasis Annu Rev Cell Biol 9 541 573 10.1146/annurev.cb.09.110193.002545
9. H Sato T Takino Y Okada 1994 A matrix metalloproteinase expressed on the surface of invasive tumor cells Nature 370 61 65 10.1038/370061a0
10. C Gilles M Polette J Piette 1996 High level of MT-MMP expression is associated with invasiveness of cervical cancer cells Int J Cancer 65 209 213 10.1002/(SICI)1097-0215(19960117)65:2<209::AID-IJC14>3.0.CO;2-8
11. H Nomura H Sato M Seiki 1995 Expression of membrane-type matrix metalloproteinase in human gastric carcinomas Cancer Res 55 3263 3266
12. PD Brown 1995 Matrix metalloproteinase inhibitors: a novel class of anticancer agents Adv Enzyme Regul 35 293 301 10.1016/0065-2571(94)00022-U
13. M Hidalgo SG Eckhardt 2001 Development of matrix metalloproteinase inhibitors in cancer therapy J Natl Cancer Inst 93 178 193 10.1093/jnci/93.3.178
14. HS Rasmussen PP McCann 1997 Matrix metalloproteinase inhibition as a novel anticancer strategy: a review with special focus on batimastat and marimastat Pharmacol Ther 75 69 75 10.1016/S0163-7258(97)00023-5
15. DC Talbot PD Brown 1996 Experimental and clinical studies on the use of matrix metalloproteinase inhibitors for the treatment of cancer Eur J Cancer 32A 2528 2533 10.1016/S0959-8049(96)00398-X
16. SA Eccles GM Box WJ Court 1996 Control of lymphatic and hematogenous metastasis of a rat mammary carcinoma by the matrix metalloproteinase inhibitor batimastat (BB-94) Cancer Res 56 2815 2822
17. RG Chirivi A Garofalo MJ Crimmin 1994 Inhibition of the metastatic spread and growth of B16-BL6 murine melanoma by a synthetic matrix metalloproteinase inhibitor Int J Cancer Res 58 3 460 464 10.1002/ijc.2910580326
18. ES Nakamura K Koizumi T Yamaura 2003 Anti-tumor angiogenic effect of a metalloproteinase inhibitor MMI270 Anticancer Res 23 1A 411 417
19. JG Naglich M June-Kunkel E Gupta 2001 Inhibition of angiogenesis and metastasis in two murine models by the matrix metalloproteinase inhibitor, BMS-275291 Cancer Res 61 8480 8485
20. KP Watts RG Fairchild DN Slatkin 1981 Melanin content of hamster tissues, human tissues, and various melanomas Cancer Res 41 467 472
21. NC Levitt FA Eskens KJ O'Byrne 2001 Phase I and pharmacological study of the oral matrix metalloproteinase inhibitor, MMI270 (CGS27023A), in patients with advanced solid cancer Clin Cancer Res 7 1912 1922
22. P Kurschat P Zigrino R Nischt 1999 Tissue inhibitor of matrix metalloproteinase-2 regulates matrix metalloproteinase-2 activation by modulation of membrane-type 1 matrix metalloproteinase activity in high and low invasive melanoma cell lines J Biol Chem 274 21056 21062 10.1074/jbc.274.30. 21056
23. UB Hofmann JR Westphal GN Van Muijen 2000 Matrix metalloproteinases in human melanoma J Invest Dermatol 115 337 344 10.1046/j.1523-1747.2000.00068.x
24. C Heyder E Gloria-Maercker F Entschladen 2002 Realtime visualization of tumor cell/endothelial cell interactions during transmigration across the endothelial barrier J Cancer Res Clin Oncol 128 533 538 10.1007/s00432-002-0377- 7
25. T Karpanen K Alitalo 2008 Molecular biology and pathology of lymphangiogenesis Annu Rev Pathol Mech Dis 3 367 397 10.1146/annurev. pathmechdis.3.121806.151515
26. EG Elias MS Didolkar IP Goel 1977 A clinicopathologic study of prognostic factors in cutaneous malignant melanoma Surg Gynecol Obstet 144 327 334
27. F Meier S Will U Ellwanger 2002 Metastatic pathways and time courses in the orderly progression of cutaneous melanoma Br J Dermatol 147 62 70 10.1046/j.1365-2133.2002.04867.x
28. UB Hofmann AA Eggert K Blass 2003 Expression of matrix metalloproteinases in the microenvironment of spontaneous and experimental melanoma metastases reflects the requirements for tumor formation Cancer Res 63 8221 8225